ABBOTT LABORATORIES— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$11.46B
↑+4.4% +$485Mvs FY2024 (Q4)
Gross Profit
$6.54B
↑+8.4% +$505Mvs FY2024 (Q4)
Operating Income
$2.25B
↑+17.8% +$340Mvs FY2024 (Q4)
Net Income
$1.78B
↑+0.1% +$1Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $11.46B | $10.97B |
| COGS | $4.92B | $4.94B |
| Gross Profit | $6.54B | $6.03B |
| R&D | $735M | $749M |
| SG&A | $3.13B | $2.91B |
| D&A | $370M | $342M |
| Other OpEx | $52M | $123M |
| Operating Income | $2.25B | $1.91B |
| Interest Exp. | $120M | $136M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $2.13B | $1.77B |
| Tax | $355M | $0 |
| Net Income | $1.78B | $1.77B |
QuarterCharts · SEC EDGAR data · ABT · Comparing FY2025 (Q4) vs FY2024 (Q4)